Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Decreased risk of cardiovascular disease in dermatology patients taking niacinamide: A TriNetX cohort study.

  • 2026-03
  • Journal of the American Academy of Dermatology 94(3)
    • Yousef Salem
    • Mahnoor Liaqat
    • Nadeen Gonna
    • Dina Zamil
    • Ferris Abu-Ghosh
    • Anwar Merie
    • Dimitri Cassimatis
    • Ida Orengo

Study Design

Type
Observational
Sample size
n = 3,231
Population
patients with multiple NMSCs
Methods
retrospective cohort study using the TriNetX platform; patients with ≥ 2 NMSCs or bullous pemphigoid who began taking oral niacinamide (≥ 500 mg) were matched 1:1 with niacinamide-naive controls

Background

Niacinamide is frequently used for nonmelanoma skin cancer (NMSC) chemoprophylaxis. Recent studies raised concerns about cardiovascular risk associated with niacin metabolites.

Objective

To evaluate the association between oral niacinamide use and cardiovascular outcomes in patients with multiple NMSCs.

Methods

We conducted a retrospective cohort study using the TriNetX platform. Patients with ≥ 2 NMSCs or bullous pemphigoid who began taking oral niacinamide (≥ 500 mg) were matched 1:1 with niacinamide-naive controls. Outcomes included various major cardiovascular events.

Results

After matching, each cohort consisted of 3231 patients. Niacinamide use was associated with reduced risk of ST elevation myocardial infarction (risk ratio 95% confidence interval P = .008), peripheral vascular disease (RR: 0.741, 95% CI: 0.605-0.909, P = .004), and cardiac arrest (RR: 0.500, 95% CI: 0.275-0.909, P = .020). Subgroup analyses by atherosclerotic cardiovascular disease history showed consistent cardiovascular benefits.

Limitations

As an observational study, causality cannot be established. The predominantly White study population and 3-year timeframe limit generalizability.

Conclusion

Niacinamide supplementation is associated with reductions in certain types of cardiovascular events, supporting its use in appropriate patient populations.

Research Insights

Back to top